Sign in
4

Changes in Ownership

Trevi Therapeutics, Inc. Filed Acc 0000950170-25-080887

Options or other derivatives

  • Chief Scientific Officer acquired 60,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
SCIASCIA THOMAS Chief Scientific Officer 2025-05-31 Grant or award · Performance Stock Option (right to buy) +60,000 92,000 D
Loading xslF345X05/ownership.xml…